About US
Contact us
-
GSK shingles shot might trump Merck's Zostavax, analysts sayThough GlaxoSmithKline ($GSK) is still waiting on late-stage results from itsshinglesvaccine, HZ/su, Cowen & Co. analysts say the GSK shot may just be better than Merck'sZostavax. The deciding fac2015/4/3
-
Pfizer shutters vaccine sales business in China after Prevenar setbackAs it beefs up its vaccines business, Pfizer's ($PFE) looking to bolster revenue from the top-sellingPrevenarfamily of shots. But on that front, it's come up against a roadblock inChina--and so it's s2015/4/3
-
Celltrion revs up Remicade biosim for U.S. rollout this yearWatch out,Remicade. South Korea-basedCelltrionis gunning to launch its biosimilar version,Remsima, in the U.S. by the end of this year. In an interview withThe Wall Street Journal, Celltrion CEO Stan2015/4/2
-
UCB hands over South Asia branded drugs to Dr. Reddy's in latest slimdown planBelgium'sUCBis slimming down, selling some of its branded products in South Asia toDr. Reddy's Laboratoriesfor $128.38 million to focus on its neurology portfolio in India. The deal hands Dr. Reddy's2015/4/2
-
Heavyweight PBMs mean trouble for Big Pharma's pricey new medsThe good news for drugmakers, after UnitedHealth ($UNH) agreed to buy Catamaran ($CTRX): You might need fewer staffers to negotiate with pharmacy benefits managers, now that 1 billion U.S. scripts a y2015/4/1
-
Indian pharma exec: Compulsory licensing cost us $10B in investmentIndia-based Hetero Pharma's director adopted a heretical position in the local pharmaceutical industry when he said use of the compulsory licensing process has costIndia$10 billion in potential invest2015/4/1
-
Gilead's huge Sovaldi payoff yields a nice 23% pay hike for CEONo one would say Gilead Sciences CEOJohn Martinis hurting financially. For several years, he has collected annual compensation worth about $15 million. Not too shabby. And his stock gains since 2009 r2015/3/31
-
Medicare takes $4.5B cost hit from superstar hep C treatmentsIndustry watchers knew Medicare would be shelling out a whole lot more on hepatitis C treatments last year, thanks to new-and-improved drugs. But just how much more did it cough up? Some $4.5 billion2015/3/31
-
Baxter pays execs more than $8.5M to stick it out through pharma spinoffBaxter ($BAX) chief Robert Parkinson--who makes a perennial appearance on the list of the top-paid helmsman in biopharma--is in prime position to return this year, despite a drop in his overall compen2015/3/30
-
Eisai gets EMA nod for Lenvima just weeks after FDA approvalEisaihas gotten its second dose of good news in as many months. Weeks after getting anFDAapproval for its thyroid cancer drug Lenvima, the struggling Japanese drugmaker has gotten the nod for the pote2015/3/30